Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy
Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance. Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the...
Saved in:
| Published in | International journal of nanomedicine Vol. 13; pp. 5113 - 5126 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Dove Medical Press Limited
01.01.2018
Taylor & Francis Ltd Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1178-2013 1176-9114 1178-2013 |
| DOI | 10.2147/IJN.S170862 |
Cover
| Abstract | Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance.
Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity.
Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D).
In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). |
|---|---|
| AbstractList | Background: Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance. Materials and methods: Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity. Results: Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX monodelivery system (HA-SiLN/D). Conclusion: In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). Keywords: gastric carcinoma, chemotherapy, quercetin, doxorubicin, co-delivery Background: Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance. Materials and methods: Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity. Results: Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D). Conclusion: In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance.BACKGROUNDEffective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance.Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity.MATERIALS AND METHODSHerein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity.Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D).RESULTSExperimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D).In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D).CONCLUSIONIn vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). Jian Fang,1,* Shangwu Zhang,2,* Xiaofeng Xue,3 Xinguo Zhu,3 Shiduo Song,3 Bin Wang,3 Linhua Jiang,3 Mingde Qin,4 Hansi Liang,4 Ling Gao3 1Department of General Surgery, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu Province, People's Republic of China; 2Department of Emergency Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China; 3Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China; 4Department of General Surgery, The Stem Cell and Biomedical Material Key Laboratory of Jiangsu Province (The State Key Laboratory Incubation Base), Soochow University, Suzhou, Jiangsu Province, People's Republic of China *These authors contributed equally to this work Background: Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance. Materials and methods: Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity. Results: Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D). Conclusion: In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). Keywords: gastric carcinoma, chemotherapy, quercetin, doxorubicin, co-delivery Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance. Herein, we developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) co-delivering quercetin and doxorubicin (DOX) to enhance the efficacy of GC therapy (HA-SiLN/QD). The HA modification was done to recognize overexpressed CD44 receptors on GC cells and mediate selective tumor targeting. In parallel, quercetin delivery decreased the expression of Wnt16 and P-glycoprotein, thus remodeling the tumor microenvironment and reversed multidrug resistance to facilitate DOX activity. Experimental results demonstrated that HA-SiLN/QD was nanoscaled particles with preferable stability and sustained release property. In vitro cell experiments on SGC7901/ADR cells showed selective uptake and increased DOX retention as compared to the DOX mono-delivery system (HA-SiLN/D). In vivo anticancer assays on the SGC7901/ADR tumor-bearing mice model also revealed significantly enhanced efficacy of HA-SiLN/QD than mono-delivery systems (HA-SiLN/Q and HA-SiLN/D). |
| Audience | Academic |
| Author | Jiang, Linhua Song, Shiduo Gao, Ling Fang, Jian Zhang, Shangwu Xue, Xiaofeng Liang, Hansi Zhu, Xinguo Wang, Bin Qin, Mingde |
| AuthorAffiliation | 4 Department of General Surgery, The Stem Cell and Biomedical Material Key Laboratory of Jiangsu Province (The State Key Laboratory Incubation Base), Soochow University, Suzhou, Jiangsu Province, People’s Republic of China 3 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People’s Republic of China, linggao0122@163.com 1 Department of General Surgery, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu Province, People’s Republic of China 2 Department of Emergency Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People’s Republic of China |
| AuthorAffiliation_xml | – name: 2 Department of Emergency Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People’s Republic of China – name: 1 Department of General Surgery, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu Province, People’s Republic of China – name: 3 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People’s Republic of China, linggao0122@163.com – name: 4 Department of General Surgery, The Stem Cell and Biomedical Material Key Laboratory of Jiangsu Province (The State Key Laboratory Incubation Base), Soochow University, Suzhou, Jiangsu Province, People’s Republic of China |
| Author_xml | – sequence: 1 givenname: Jian surname: Fang fullname: Fang, Jian – sequence: 2 givenname: Shangwu surname: Zhang fullname: Zhang, Shangwu – sequence: 3 givenname: Xiaofeng surname: Xue fullname: Xue, Xiaofeng – sequence: 4 givenname: Xinguo surname: Zhu fullname: Zhu, Xinguo – sequence: 5 givenname: Shiduo surname: Song fullname: Song, Shiduo – sequence: 6 givenname: Bin surname: Wang fullname: Wang, Bin – sequence: 7 givenname: Linhua surname: Jiang fullname: Jiang, Linhua – sequence: 8 givenname: Mingde surname: Qin fullname: Qin, Mingde – sequence: 9 givenname: Hansi surname: Liang fullname: Liang, Hansi – sequence: 10 givenname: Ling surname: Gao fullname: Gao, Ling |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30233175$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkkuP0zAURiM0iHnAij2yxAYJtdjxK9kgjUY8ikYgBKwtx75uXSV2sZMR3fLLcWkHpqNJFkmcc0_yWd95dRJigKp6TvC8Jky-WXz6PP9GJG5E_ag6I0Q2sxoTenLn_rQ6z3mNMZeNaJ9UpxTXlBLJz6rfXydIBkYfkA4W2fgrpqnzpjybOLPQ-xtIWzRlH5ZogBw3McUpo-x7bzQKOsSNTqM3PWQEYaWDATSuAIFzBTBbFB1a6jwmb5DRqYjjoJFZwRALlvRm-7R67HSf4dnhelH9eP_u-9XH2fWXD4ury-uZ4aweZ5p0grNWaNfRznFtO22cw62grqENp7KpKUgGICXXLQgpLCeMdMBtK7Ag9KJa7L026rXaJD_otFVRe_V3IaalOiRRwgAXRMtaaGAt552lvDGUW2ZFy4gprrd712bqBrAGwph0fyQ9fhP8Si3jjSr_wWvCi-DVQZDizwnyqAafDfS9DlD2V9WkHIxhsUNf3kPXcUqhbJWqa9pKSQXG_6mlLgF8cLF81-yk6pI3lDUNFqxQ8weocloYvCm9cr6sHw28uBv0X8LbBhWA7AGTYs4JnDJ-1KOPu9y-VwSrXUtVaak6tLTMvL43c6t9iP4Ds9noxw |
| CitedBy_id | crossref_primary_10_1016_j_jare_2024_08_005 crossref_primary_10_1016_j_ijbiomac_2021_10_142 crossref_primary_10_1186_s11671_019_3143_3 crossref_primary_10_1039_D1FO00851J crossref_primary_10_1016_j_arabjc_2021_103266 crossref_primary_10_2174_1871520623666230817101926 crossref_primary_10_3390_molecules25112597 crossref_primary_10_3390_pharmaceutics13020143 crossref_primary_10_1016_j_jconrel_2021_06_034 crossref_primary_10_1166_mex_2023_2519 crossref_primary_10_1016_j_onano_2022_100081 crossref_primary_10_1016_j_ijpharm_2023_122763 crossref_primary_10_3390_pharmaceutics14122770 crossref_primary_10_1186_s12943_019_0992_4 crossref_primary_10_1080_1061186X_2020_1775839 crossref_primary_10_3389_fphar_2022_829796 crossref_primary_10_1016_j_jddst_2024_106421 crossref_primary_10_2174_1574892816666210929165729 crossref_primary_10_1007_s42247_024_00845_4 crossref_primary_10_1080_10717544_2022_2094498 crossref_primary_10_1038_s41430_020_0684_6 crossref_primary_10_3390_pharmaceutics14010018 crossref_primary_10_1080_15376516_2023_2188928 crossref_primary_10_3233_JBR_180364 crossref_primary_10_1080_17425247_2019_1645115 crossref_primary_10_1016_j_bioactmat_2021_11_027 crossref_primary_10_1016_j_apsusc_2021_150011 crossref_primary_10_1134_S0003683822090149 crossref_primary_10_1016_j_jddst_2022_103231 crossref_primary_10_3390_cancers14174123 crossref_primary_10_1016_j_jconrel_2023_07_061 crossref_primary_10_1038_s41467_020_20588_0 crossref_primary_10_1080_10837450_2019_1684944 crossref_primary_10_1016_j_biopha_2019_109473 crossref_primary_10_1016_j_semcancer_2020_01_006 crossref_primary_10_1038_s41598_019_46007_z crossref_primary_10_3390_surgeries5010007 crossref_primary_10_1016_j_taap_2023_116405 crossref_primary_10_1002_wnan_1605 crossref_primary_10_2174_1568026620666200502005411 crossref_primary_10_3390_molecules27175452 crossref_primary_10_1557_jmr_2020_321 crossref_primary_10_1039_D4NR03040K crossref_primary_10_1038_s41578_020_0230_0 crossref_primary_10_1016_j_biopha_2023_114955 crossref_primary_10_1016_j_biopha_2025_117909 crossref_primary_10_1002_adfm_202109460 crossref_primary_10_2174_0929867330666230502113150 crossref_primary_10_1088_2399_1984_acf822 crossref_primary_10_1002_smll_201902242 crossref_primary_10_1016_j_addr_2022_114445 crossref_primary_10_1016_j_colsurfb_2020_111284 crossref_primary_10_1016_j_ijpharm_2022_122342 crossref_primary_10_1016_j_semcancer_2019_08_029 crossref_primary_10_1021_acsbiomaterials_0c00042 crossref_primary_10_3389_fchem_2022_844426 crossref_primary_10_1016_j_ijbiomac_2019_10_060 crossref_primary_10_1039_C9TB02131K crossref_primary_10_1016_j_apsb_2023_12_001 crossref_primary_10_1016_j_semcancer_2020_06_014 crossref_primary_10_1080_21655979_2021_1971507 crossref_primary_10_1016_j_smaim_2025_01_002 crossref_primary_10_1016_j_ijpharm_2022_121942 crossref_primary_10_1016_j_drudis_2021_09_020 crossref_primary_10_3390_cells9030589 crossref_primary_10_1016_j_biopha_2021_111632 crossref_primary_10_1007_s40097_021_00398_6 crossref_primary_10_1016_j_biopha_2023_114505 crossref_primary_10_1016_j_fct_2020_111820 crossref_primary_10_3390_pharmaceutics14061131 crossref_primary_10_1080_13813455_2020_1773864 crossref_primary_10_1016_j_jddst_2022_103938 crossref_primary_10_1007_s00432_021_03520_x crossref_primary_10_1016_j_onano_2022_100074 crossref_primary_10_1016_j_drudis_2022_103409 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Dove Medical Press Limited 2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 Fang et al. This work is published and licensed by Dove Medical Press Limited 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 Dove Medical Press Limited – notice: 2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 Fang et al. This work is published and licensed by Dove Medical Press Limited 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.2147/IJN.S170862 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1178-2013 |
| EndPage | 5126 |
| ExternalDocumentID | oai_doaj_org_article_6ce561a726ae4955bd358c35d4d6941c PMC6135215 A583488064 30233175 10_2147_IJN_S170862 |
| Genre | Journal Article |
| GeographicLocations | United States--US China |
| GeographicLocations_xml | – name: China – name: United States--US |
| GroupedDBID | --- 0YH 29J 2WC 53G 5GY 5VS 7X7 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AEGXH AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 DIK DU5 DWQXO E3Z EBD EBS EJD EMOBN F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR ITC KQ8 M2O M48 MM. O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM SJN SV3 TDBHL TR2 UKHRP VDV CGR CUY CVF ECM EIF M~E NPM PMFND 3V. 7XB 8FK K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c542t-a1b65496afb3bf5adbacff0963f838537823e74ee775a9e676d5141be5d960613 |
| IEDL.DBID | M48 |
| ISSN | 1178-2013 1176-9114 |
| IngestDate | Wed Aug 27 01:30:23 EDT 2025 Thu Aug 21 18:40:34 EDT 2025 Fri Sep 05 08:51:59 EDT 2025 Mon Jun 30 09:09:35 EDT 2025 Tue Jun 17 21:41:34 EDT 2025 Tue Jun 10 20:26:59 EDT 2025 Thu Jan 02 22:54:08 EST 2025 Tue Jul 01 03:52:08 EDT 2025 Thu Apr 24 23:10:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | co-delivery quercetin doxorubicin gastric carcinoma chemotherapy |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c542t-a1b65496afb3bf5adbacff0963f838537823e74ee775a9e676d5141be5d960613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work |
| OpenAccessLink | https://doaj.org/article/6ce561a726ae4955bd358c35d4d6941c |
| PMID | 30233175 |
| PQID | 2239773600 |
| PQPubID | 3933144 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6ce561a726ae4955bd358c35d4d6941c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6135215 proquest_miscellaneous_2111144065 proquest_journals_2239773600 gale_infotracmisc_A583488064 gale_infotracacademiconefile_A583488064 pubmed_primary_30233175 crossref_citationtrail_10_2147_IJN_S170862 crossref_primary_10_2147_IJN_S170862 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | International journal of nanomedicine |
| PublicationTitleAlternate | Int J Nanomedicine |
| PublicationYear | 2018 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Medical Press |
| SSID | ssj0057869 |
| Score | 2.4943037 |
| Snippet | Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug resistance.... Background: Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug... Effective gastric carcinoma (GC) chemotherapy is subject to many in vitro and in vivo barriers, such as tumor microenvironment and multidrug... Jian Fang,1,* Shangwu Zhang,2,* Xiaofeng Xue,3 Xinguo Zhu,3 Shiduo Song,3 Bin Wang,3 Linhua Jiang,3 Mingde Qin,4 Hansi Liang,4 Ling Gao3 1Department of General... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 5113 |
| SubjectTerms | Analysis Animals Anthracyclines Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Biomedical materials Cancer Cancer therapies Cancer treatment Carcinoma Cell adhesion & migration Cell Death Cell Line, Tumor Chemotherapy co-delivery Colloids Deoxyribonucleic acid DNA doxorubicin Doxorubicin - administration & dosage Doxorubicin - therapeutic use Drug Delivery Systems Drug Liberation Drug resistance Fibroblasts Gastric cancer gastric carcinoma Growth factors Humans Hyaluronic acid Laboratory animals Male Medical prognosis Metastasis Mice, Inbred BALB C Microbial drug resistance Nanoparticles Nanoparticles - chemistry Nanoparticles - ultrastructure Original Research Particle Size Porosity Quantum Dots - chemistry quercetin Quercetin - administration & dosage Quercetin - therapeutic use Silicon dioxide Silicon Dioxide - chemistry Spheroids, Cellular - drug effects Spheroids, Cellular - metabolism Spheroids, Cellular - pathology Static Electricity Stomach cancer Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Surgery Time Factors Tissue Distribution - drug effects Treatment Outcome Tumor Burden - drug effects Tumors Wnt Proteins - metabolism |
| SummonAdditionalLinks | – databaseName: WRHA-DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF-kT_ogfhutskJBEGJJ9iPZxyqWWrAgWujbsh-T9qC3kd4d9F77lzuTzR0XFHwxTyG7gezM7MxvNvPB2EHn0UtutCmFcVDK4HRplBN4Jw2qwrqOnvKdv53pk3N5eqEudlp9UUxYLg-cCXeoA6CJd02tHSCYVz4K1QahooyUgxlI-6IZ2zhTWQejGA7N7KqqITmoRM7Mo548h19Pzz7-qBqC8hNbNJTs_1Mx71imadTkjhk6fsQejviRH-XvfszuQXrCHuxUFXzK7r6vKFplOUvcpchjf9vfrDz9QeehLyNcUyjGmlPE-yWfw6JHCI7-P1_M6ACPJ5fQkR7j5TikK5ILjjiRA5WbcGHN-45fOmr4EXigXkSpnzuO3J-P6VzrZ-z8-MvPzyfl2GqhDErWy9JVXqOnqF3nhe-Ui96FrkP3RnStQIuOOEJAIwGaRjkDutERkVblQUVygSrxnO2lPsFLxk3nQFexpaMUKbw0YHTtjRSADmtUsWAfNkS3YaxDTu0wri36I8QhixyyI4cKdrCd_CuX3_j7tE_Eve0Uqpk9PEBJsiPF7L8kqWDvifeWdjZ-ENIzJyjgsqhGlj1SrSB1p2XB9iczcUeG6fBGeuyoERYWYRhCbYH4smDvtsP0JkW5JUA-47LwkgixVMFeZGHbLomaOxHWK1gzEcPJmqcjaXY11AtH9iBIU6_-B5Fes_u4n9p8CLXP9pY3K3iDsGzp3w478DemRTXR priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vuiD-N1olRUKghBLsl_Jk1Sx1IIF0cK9hf3K9aC3W-8DvNf-5Z1J9uIFxTyF7AayO7Mzv5nMByGHrQErWck6Z7X2Obda5rXQDO54DaKwLJ3BfOdv5_L0gp9NxCQ53JYprHIrEztB7aJFH_kRqDGAKgz088frXzl2jcK_q6mFxl1yrwCoglytJoPBBczYtbQrCiXxUPM-Pw878xx9PTv_8KNQCOhHGqkr3P-3eN7RT-PYyR1ldPKIPEwokh73ZH9M7vjwhDzYqS34lNx8X2PMymoWqA6Ouvg7LtYG_6NTG3PnrzAgY0Mx7n1K534ZAYjH9ZIuZ-jGo0EHMKdT1Bz14RK5gwJapB6LTmi7obGlU41tPyy12JEoxLmmwAPzlNS1eUYuTr78_Hyap4YLuRW8XOW6MBLsRalbw0wrtDPati0YOaytGOh1QBPMK-69UkLXXirpAG8VxguHhlDBnpO9EIPfJ7RutZeFq9Chwpnhta9laWrOPJitTriMvN9uemNTNXJsinHVgFWCFGqAQk2iUEYOh8nXfRGOf0_7hNQbpmDl7O5BXEybtGONtB4go1al1B6MQ2EcE5VlwnGHOb02I--Q9g2eb_gg2M8-TQGWhZWymmNRMRR6kmfkYDQTzqUdD2-5p0lyYdn84eKMvB2G8U2MdQse6AzLgosD0BIZedEz27AkbPGEiC8jasSGozWPR8LssqsaDuQBqCZe_v-zXpH7AAmr3sl0QPZWi7V_DbBrZd50Z-sWpDUtiQ priority: 102 providerName: ProQuest |
| Title | Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30233175 https://www.proquest.com/docview/2239773600 https://www.proquest.com/docview/2111144065 https://pubmed.ncbi.nlm.nih.gov/PMC6135215 https://doaj.org/article/6ce561a726ae4955bd358c35d4d6941c |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: KQ8 dateStart: 20090101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: KQ8 dateStart: 20060101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: DIK dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: GX1 dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: 7X7 dateStart: 20120101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: BENPR dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal: Open Access Journals [open access] customDbUrl: eissn: 1178-2013 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: M48 dateStart: 20060301 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1178-2013 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057869 issn: 1178-2013 databaseCode: 0YH dateStart: 20060901 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Ja9tAFB6yXNpD6V61qZlCoFBQWmk26VBKUhLcQEw3g3sSs8kx2KPWC8TX_vK-J8nGakN1MMIzAs1738x8b_QWQo5LA1ayknnMcu1jbrWMc6EZ3PEclsI0dQbjna8Gsj_klyMx2iObYpytABe3mnZYT2o4n57c_Fp_gAn_Ht2YE67efrocnHxLFJLzfXIIW1KK8L7i288JgMq6tl2SKIRFwppAvb8f7mxNdQb_f9fpnY2q60S5sytd3Cf3WjpJTxv9PyB7Pjwkd3eSDD4iv7-s0HllOQlUB0dddVPNVwY_qFNbxc5P0TNjTdEBfkxnflGBMKrVgi4meJ5Hgw5gV7fuc9SHa4QJBdpIPWaf0HZNq5KONdb_sNRiaaJQzTQFMMza6K71YzK8OP_-sR-3lRdiK3i6jHViJBiOUpeGmVJoZ7QtS7B2WJkx2OCBVjCvuPdKCZ17qaQD4pUYLxxaRAl7Qg5CFfwzQvNSe5m4DE9WODM897lMTc6ZB_vVCReRNxuhF7ZNS47VMaYFmCeooQI0VLQaisjxtvPPJhvH7d3OUHvbLphCu_6jmo-LVmKFtB64o1ap1B6sRGEcE5llwnGHwb02Iq9R9wVCD14I5NnEK8CwMGVWcSoyhquf5BE56vSECWq7zRv0FBt8F8DKgHkzoJsRebVtxifR6S140DMMCy4OjEtE5GkDtu2QsNYTUr-IqA4MO2PutoTJdZ0-HNQDnE08__9bvyB3YKZkzWnTETlYzlf-JfCvpemR_Xc_-vCrRqpHDs_OB5-_9uqzjF496_4A31IzpQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VcgAOFW9cCixSERKSKfY-HB8QKo8q6SMSopVyW_blNFKzLnkIcuUH8RuZsZ0QC8StOVnZTeTdGc98s56Zj5DdwkCUnMk8Zrn2MbdaxrnQDK54DqYwTZ3BeueTvuye8cOBGGyQX8taGEyrXNrEylC70uIZ-R64MYAqDPzzu8tvMbJG4dvVJYVGrRZHfvEdQrbp295HkO-LND34dPqhGzesArEVPJ3FOjESgiKpC8NMIbQz2hYFIHlWdBg4L3CZzGfc-ywTOvcykw5ARWK8cIj2Ewb_e41c5-wNx1792WAV4IHyVxR6SZJJNCK8rgdEJqC93mH_9ZckwwCi5QErooC_3cGaP2znaq45v4PbZKtBrXS_VrM7ZMOHu-TWWi_De-Tn5znmyMxGgergqCt_lJO5wff21Jax8xeYALKgmGc_pGM_LQH4l_MpnY7w2JAGHSB8b7L0qA_nqI0U0Cn12ORC2wUtCzrUSDNiqUUGpFCONQWdGzdFZIv75OxKRPGAbIYy-EeE5oX2MnEdPMDhzPDc5zI1OWcewmQnXEReLTdd2ab7OZJwXCiIglBCCiSkGglFZHc1-bJu-vHvae9Reqsp2Km7-qKcDFWzY0paDxBVZ6nUHoJRYRwTHcuE4w5riG1EXqLsFdoTuCHYz7osApaFnbnUvugwNLKSR2SnNRPsgG0PL7VHNXZoqv48NRF5vhrGX2JuXfAgZ1gWfDgAOxGRh7WyrZaElFKIMCOStdSwteb2SBidV13KQTwADcX2_2_rGbnRPT05Vse9_tFjchPgaKc-4Nohm7PJ3D8ByDczT6vnjJKvV_1g_wbFIGpZ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB6VIiE4VOwYCgxSERKSiexZHB8QKpSoaSECQaXchtmcRmrGbRZBrvwsfh3v2U6IBeLWnKzM2PLM2743fgshe4UBLzmTecxy7WNutYxzoRlc8RxUYZo6g_nOHwfy8IQfDcVwi_xa5cJgWOVKJ1aK2pUWz8g7YMYAqjCwz52iCYv4dNB7c34RYwcp_NK6aqdRs8ixX34H9232un8AtH6epr33X98dxk2HgdgKns5jnRgJDpLUhWGmENoZbYsCUD0rugwMGZhP5jPufZYJnXuZSQcAIzFeOET-CYPnXiFXM8YZhpNlw7WzB4JQtdNLkkyiQuF1biB2Ber0jwavviQZOhMta1g1DfjbNGzYxnbc5oYh7N0kOw2Cpfs1y90iWz7cJjc26hreIT8_LzBeZj4OVAdHXfmjnC4MfsOntoydP8NgkCXFmPsRnfhZCU5AuZjR2RiPEGnQAVz5JmKP-nCKnEkBqVKPBS-0XdKyoCONLUcstdgNKZQTTYH_Jk1C2fIuObkUUtwj26EM_gGheaG9TFwXD3M4Mzz3uUxNzpkHl9kJF5GXq01XtqmEjg05zhR4REghBRRSDYUisreefF4XAPn3tLdIvfUUrNpd_VFOR6rZMSWtB7iqs1RqD46pMI6JrmXCcYf5xDYiL5D2CnULvBDsZ50iAcvCKl1qX3QZKlzJI7Lbmgk6wbaHV9yjGp00U38kKCLP1sN4J8bZBQ90hmXBjwPIExG5XzPbeknYXgrRZkSyFhu21tweCePTqmI5kAdgonj4_9d6Sq6BSKsP_cHxI3IdkGm3PuvaJdvz6cI_BvQ3N08qMaPk22XL9W-xeG6U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quercetin+and+doxorubicin+co-delivery+using+mesoporous+silica+nanoparticles+enhance+the+efficacy+of+gastric+carcinoma+chemotherapy&rft.jtitle=International+journal+of+nanomedicine&rft.au=Fang%2C+Jian&rft.au=Zhang%2C+Shangwu&rft.au=Xue%2C+Xiaofeng&rft.au=Zhu%2C+Xinguo&rft.date=2018-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-2013&rft.volume=13&rft.spage=5113&rft_id=info:doi/10.2147%2FIJN.S170862&rft.externalDocID=A583488064 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-2013&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-2013&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-2013&client=summon |